SIRT1 and type 1 diabetes mellitus: Using a non-immune mediated streptozotocin model of type 1 diabetes, here we show that administration of an allosteric activator of SIRT1, SRT3025, led to substantial improvement in glycaemic control in the absence of any demonstrable effect on ß-cell mass, insulin secretion or insulin sensitivity.